AdipoLABs' High Frequency Hyperthermia Cancer Treatment Device 'REMISSION 1℃' Accelerates Its Conquest in China

Participation in the 8th China Chengdu International Nursing Care Service Industry Expo… Sharing ‘REMISSION 1℃’ hyperthermia and immunotherapy cases

CEO Han Sung-ho presents cooperation measures to promote friendly medical relations between the two countries, including a medical tourism roadmap

▲ (From left in the photo) Medifuture CEO Bae Dae-seung, Chengdu Korean-Chinese Cultural Association Chairman Park Won-seo, Chengdu Cancer Association Chairman Wang Qingquan, Consul General of the Republic of Korea in Chengdu Eom Won-jae, Chengdu Nursing Association Chairman Hwang Jae-gun, AdipoLabs CEO Han Sung-ho, Seoul St. Mary's Hospital Professor Jang Hong-seok, Yonsei Line Hospital Director Ahn Seong-hwan, Guangzhou Kang'an Liyang Medical Technology Co., Ltd. CEO Yan Bin, Sichuan Hospital Association Secretary Liu Qiang, and Chengdu Century Gangbo Quanse Association Co., Ltd. CEO Wen Ze.

【Health and Welfare News】 AdipoLabs Co., Ltd. (CEO Han Sung-ho), a leader in the global cancer treatment device market, is actively promoting and distributing advanced domestic medical technologies for cancer treatment in China, thereby accelerating its advance into the Chinese market.

AdipoLABs Co., Ltd. announced that it participated in the 8th China Chengdu International Nursing Service Industry Expo and International Conference held in Chengdu, Sichuan Province, China from the 7th to the 9th.

In particular, at this exhibition, AdipoLABs set up an integrated booth under the name of ‘KOREA MEDICAL CENTER’ and actively informed visitors about medical tourism related to cancer treatment, hyperthermia using the high-frequency hyperthermia cancer treatment device called ‘REMISSION 1℃’, and cases of immunotherapy cancer treatment, as well as treatment principles.

In addition, it was emphasized that ‘REMISSION 1℃’ is at the center of domestic cancer treatment hospitals and medical professionals interested in medical tourism business to attract Chinese cancer patients.

AdipoLABs' high-frequency hyperthermia cancer treatment device ' REMISSION 1℃' is a medical device that raises our body temperature to over 40℃, improves blood circulation and immunity, and is used for cancer treatment and pain relief.

In addition, ' REMISSION 1℃' is a medical device that supports the IVRA (International Virus Research Alliance) every year, and has been attracting attention from medical professionals at home and abroad by verifying its academic effectiveness in cancer treatment and pain management in many countries internationally.

On the other hand, the ‘International Conference on Treatment of Korean and Chinese Cancer Patients’ was held at the 2nd building of the Chengdu Century International Exhibition Center on the 8th.

At this conference, Professor Jang Hong-seok of the Catholic University of Korea Seoul St. Mary’s Hospital, Director Yoo Seung-mo of Yesan Myongji Hospital, Director Lee Chan-yong of Seoul Oncare Hospital, Director Ahn Seong-hwan of Yonsei Line Hospital, and Han Sung-ho, CEO of AdipoLABs and IVRA, participated as speakers and gave presentations.

In addition, from China, Vice Chairman Wang Qingquan of Sichuan Red Cross Society, Vice Chairman Mao Zenglin of Degindang Holdings, Chairman Huang Zaijun of the Party Committee of Chengdu Emperor Military Hospital and Huang Rheumatism Group, President Shu Fengcheng of Dujiang Yan Fengcheng Pain Hospital, and DR. Kenny Yong yean-sirn from Malaysia attended the event and made in-depth presentations on the latest cancer treatment technologies and cooperation plans, attracting much attention.

▲ AdipoLABs CEO Han Sung-ho explains the Korea-China medical tourism business and the operating principle of the high-frequency hyperthermia cancer treatment device ‘REMISSION 1℃’.

Specifically, CEO Han Sung-ho presented a roadmap for medical tourism, a common interest between Korea and China, and proposed cooperation measures to promote friendly medical relations between the two countries, and asked for active participation in the 8th ‘2025 IVRA International Medical Conference’ to be held at Seoul St. Mary’s Hospital on June 22. CEO Han Sung-ho said, “We will do our best to spread and promote advanced domestic medical technologies for cancer treatment, starting with China,” and “We will aggressively market to the Chinese market through this exhibition.”

AdipoLABs Inc. expected that this exhibition and conference would serve as a stepping stone for expanding medical cooperation between Korea and China and entering the global market.

Meanwhile, the exhibition and conference, hosted by Chengdu Century Obsessive-Compulsive Exhibition Co., Ltd. in China and organized by AdipoLABs Co., Ltd., IVRA, SKFI Korea-China Future Innovation Booster, Sichuan Province Traditional Chinese Medicine Technology Research Association, Chengdu Cancer Association, Chengdu Medical and Health Expo Organizing Committee, and Chengdu International Nursing Service Industry Expo Organizing Committee, was attended by leading domestic cancer treatment hospitals such as Seoul Oncare Hospital, Amirang Hospital, Yesan Myeongji Hospital, and Chihyu Oriental Medicine Hospital, as well as pharmaceutical and health food companies such as Nature's Farm, Red & Blue, and Medifuture, as well as officials from IVRA.

In addition, 200 companies from China, including Sichuan Hospital Association, Chengdu Cancer Association, Chengdu Nursing Home Association, Deokindang Group, and Chengdu Kangbei City Co., Ltd., participated in the exhibition event.

Source: https://m.whosaeng.com/159388